Human papillomavirus (HPV) type 16 and 18 E6 proteins target many of their cellular substrates for proteasomemediated degradation. In the case of p53, this is mediated by the E6AP ubiquitin ligase. However it is still unclear whether other E6 substrates, in particular those containing PDZ domains, are also degraded in a similar manner. To investigate this, we established an epithelial cell line from E6AP-null mice and used these cells as a background to perform E6-mediated in vivo degradation assays. We show that the PDZ domain-containing substrates of E6, including Scribble, MAGI-1 and MAGI-3, are all subject to E6-mediated degradation in these cells. Strikingly, we also found that p53 could be degraded by E6 within these cells in a proteasome-dependent manner. These results demonstrate that HPV-16 and -18 E6 can target substrates for degradation in a manner independent of the E6AP ubiquitin ligase.
Induction of cervical cancer by high-risk HPV requires the concerted action of two viral oncoproteins, E6 and E7. The E7 oncoprotein is largely responsible for perturbing cell cycle progression through targeting, among others, the pRb family of tumour suppressors (Munger et al., 2001 for review). In turn, the E6 oncoprotein counteracts the cellular response to unscheduled proliferation by targeting p53 for proteasome-mediated degradation (Thomas et al., 1999b for review) . This activity of E6 is largely restricted to those proteins derived from virus types associated with the development of cervical cancer (Scheffner et al., 1990) , in particular HPV-16 and -18 (zur Hausen, 1996) . A number of studies have shown that degradation of p53 by E6 requires the recruitment of the E6AP cellular ubiquitin ligase to the complex, thereby allowing the polyubiquitination of p53 and its subsequent degradation by the proteasome Scheffner et al., 1993) . Although degradation of p53 is a critical part of E6's function, it is also clear that other activities of E6 are important for promoting the development of malignancy (Nguyen et al., 2003) . Perhaps, the most important of these are E6's interactions with the PDZ domain-containing substrates. HPV E6 recognizes these proteins through a very short (4 amino acid) motif that is found at the extreme C terminus only in those E6 proteins that are associated with the development of cervical cancer (Kiyono et al., 1997; Lee et al., 1997) . Mutation of this region in E6 reduces its transforming activity, decreases viral replication and keratinocyte immortalization (Lee and Laimins, 2004) , and significantly impairs the ability of E6 to induce epithelial hyperplasia in transgenic mice (Nguyen et al., 2003) .
To date, several PDZ domain-containing substrates of E6 have been described. Many of these are involved in processes regulating cell polarity, cell-cell contact and cell proliferation. These include Discs Large (Dlg), Scribble (Scrib), the MAGI family of proteins, MUPP1 and PATJ (Gardiol et al., 1999; Glaunsinger et al., 2000; Lee et al., 2000; Nakagawa and Huibregtse, 2000; Thomas et al., 2002; Latorre et al., 2005) . In all cases, the HPV E6 proteins can target these cellular substrates for proteasome-mediated degradation. However, the relative efficiency with which HPV-16 and -18 E6 can do this varies depending upon the particular PDZ domaincontaining protein. This variation is caused by a critical difference in the amino-acid residue at the extreme C termini of the two E6 proteins (Thomas et al., 2005) . Previous studies have suggested that E6AP is involved in HPV-16 E6-mediated degradation of Scrib (Nakagawa and Huibregtse, 2000) ; however, the situation with the other PDZ domain containing substrates is less clear, as Dlg and MAGI would appear to be targeted in vitro by E6 in a manner at least partly independent of E6AP (Pim et al., 2000; Grm and Banks, 2004) .
To further investigate the contribution of E6AP to the E6-induced degradation of PDZ domain-containing substrates, we have made use of an E6AP-null mouse strain (Jiang et al., 1998) . To generate an epithelial cell line from these mice, kidneys were removed from 9-dayold mice and transfected with plasmids expressing Adenovirus E1a and an activated EJ-ras oncogene. Immortalized cultures were obtained after 2 weeks of selection, which were then expanded to a series of different cell lines. Of these, a clone (8B-9) with stable growth characteristics and epithelial morphology was chosen for the study. To verify that these cells were truly E6AP-null, we performed PCR analysis, the results of which are shown in Figure 1a . As can be seen, line 8B-9 is completely devoid of the E6AP locus. This was further verified by performing western blot analysis for E6AP on these cells (Figure 1b) .
Having established an epithelial cell line that was null for E6AP, we then proceeded to investigate the ability of E6 to target some of its various cellular substrates for degradation in these cells. For comparison, we also performed the same assays in HEK293 cells. Both sets of cells were transfected using calcium phosphate precipitation with an HA-tagged Scrib expressing plasmid in the presence or absence of HPV-18 E6. Proteasome inhibitors CBZ/LLnl (Z-Leu-Leu-Leu-al/Calpain inhibitor I) were also included 2 h prior to harvesting the cells in order to determine whether any induced degradation was proteasome mediated. After 24 h, the cells were harvested and the proteins were detected by western blot analysis with anti-HA antibodies. The results obtained are shown in Figure 2 and, as can be seen, the levels of Scrib are significantly lower in the presence of HPV-18 E6 both in HEK293 cells and in the E6APÀ/À cells. In the absence of E6, Scrib is also stabilized with roughly equal efficiency in both cell lines, confirming that the proteasome in the E6APÀ/À cells is functional. However, the ability to rescue Scrib from E6-induced degradation by proteasome inhibition in both cell lines is modest. These results suggest that E6 can reduce the level of expression of Scrib in an E6AP-independent manner, but that this may be only partially dependent upon the proteasome machinery.
To further investigate the ability of E6 to target proteins for degradation in the absence of E6AP, we (1) 
A combination of primers (1) plus (2) amplifies the wild-type E6AP locus and gives a product of approximately 800 bp (top panel), while primers (2) plus (3) are specific for the deleted locus and amplify a product of approximately 350 bp in size (bottom panel). Shown are samples from 8B-9 cells and appropriate controls. (b) Western blot analysis of E6AP. Shown is an immunoblot of total protein lysates isolated from epidermal scrapes of skin from 9-day-old mice, resolved on a sodium dodecyl sulphate-polyacrylamide (SDS-PAGE) gel. The gel was transferred onto a PVDF membrane and incubated with an antibody specific to E6AP (UBE3A, BD Pharmingen at 1:500, Milan, Italy). A mouse anti-HRP secondary antibody (Jackson Immunoresearch, Milan, Italy) was applied at 1:20 000 and detection was done using ECL Plus (Amersham, Italia S.r.l., Milan, Italy). Shown are samples from early passage (p11) and late passage (p50) 8B-9 cells as well as the indicated controls. Figure 2 HPV-18 E6-induced degradation of Scrib in HEK293 and E6AP-null cells. Cells were transfected with 2 mg of the HA tagged-Scrib (Thomas et al., 2005) expression plasmid together with 5 mg of the HPV-18 E6 expression plasmid (Thomas et al., 2005) , as indicated, plus 2 mg of the pCDNA-HisLacZ expression plasmid (Invitrogen, Italia S.R.L., Milan, Italy), using calcium phosphate precipitation. After 24 h, the cells were incubated for 2 h with a combination of CBZ/LLnL (final concentrations 50 mM; Sigma-Aldrich distributed by Italian Biotechnology Directory, Milan, Italy) to block the proteasome, with DMSO treatment as the control. The cells were then harvested and proteins detected using western blotting with anti-HA antibody (1:500 dilution; Roche Diagnostics, S.p.A., Milan, Italy), followed by HRP-coupled anti-mouse antibody (1:1000 dilution; DAKO, Italia S.p.A., Milan, Italy) and ECL detection (Amersham, Italia S.r.l., Milan, Italy). The blot was re-probed with an anti-b-galactosidase (LacZ 1:5000 dilution; Promega, Italia S.R.L., Milan, Italy) antibody to monitor protein loading and transfection efficiency. Arrows indicate the position of the Scrib and LacZ proteins. The gels were scanned and the percentage changes in Scribble levels following CBZ protection (prot.), E6 degradation (degr.) and CBZ-induced recovery from degradation (rec.) are indicated. When LacZ expression levels are also taken into account the recovery is in the order of 20% in the E6APÀ/À cells. The results are representative of between 3 and 6 separate experiments.
cells
extended the analysis to MAGI-1 and MAGI-3, which we had previously shown could be degraded in vitro by E6 in the absence of E6AP (Grm and Banks, 2004) . The results obtained are shown in Figure 3 . In HEK293 cells, MAGI-3 is highly susceptible to E6-induced degradation and this is efficiently rescued following proteasome inhibition, which is in agreement with previous studies (Thomas et al., 2002) . In the E6AP null cells, HPV-18 and -16 E6 induce MAGI-3 degradation more weakly and, furthermore, this is not rescued following proteasome inhibition. In addition, MAGI-3 by itself, unlike Scrib, appears not to be intrinsically regulated by the proteasome in these two different cell lines. In the case of MAGI-1, it is also subject to E6-induced degradation in the E6AP null cells, but again this appears to be largely independent of the proteasome machinery, since treatment with CBZ/LLnl has no significant effect on the levels of MAGI-1 expression in the presence of HPV-16 E6.
Since previous studies had clearly shown that p53 was degraded by E6 in an E6AP-dependent manner (Scheffner et al., 1993), we also investigated the ability of E6 to target p53 in our E6AP-null epithelial cells. Assays were done as above, using a human p53 expression plasmid together with HPV-16 E6 and -18 E6 for comparison. After 24 h, cells were either treated or not treated with proteasome inhibitors, in order to assess whether any reduction in the levels of p53 is dependent upon proteasome-mediated degradation. The levels of p53 protein were then detected by western blot analysis using the human-specific monoclonal antibody DO-1, and the results obtained are shown in Figure 4 Figure 3 Degradation of MAGI-1 and MAGI-3 in E6AP-null cells. The 8B-9 and HEK293 cells were transfected with 3 mg of the HAtagged MAGI-1 expression plasmid , or 3 mg of the V5-tagged MAGI-3 expression plasmid (Thomas et al., 2005) , together with 5 mg of the HPV-16 and -18 E6 expression plasmids, as indicated, plus 2 mg of the pCDNA-HisLacZ expression plasmid (Invitrogen), using calcium phosphate precipitation. After 24 h, the cells were incubated for 2 h with a combination of CBZ/ LLnL (final concentrations 50 mM) to block the proteasome, with DMSO treatment as the control. Cells were then harvested and proteins detected using western blotting with anti-HA (Roche Diagnostics) and anti-V5 (1:5000 dilution; Promega) antibodies together with either anti-b-galactosidase antibody (LacZ; Promega) or anti-GFP (Clontech distributed by Celbio s.p.a., Milan, Italy), followed by anti-mouse HRP conjugate (DAKO) and developed using ECL (Amersham). The gels were scanned and the percentage changes in MAGI-3 and MAGI-1 levels following CBZ protection (prot.), E6 degradation (degr.) and CBZ-induced recovery from degradation (rec.) are indicated. When LacZ expression levels are taken into account the recovery is in the order of 20% for MAGI-1. The results are representative of between 3 and 6 separate experiments.
HPV E6 degradation of p53 P Massimi et al be seen, both HPV-16 and -18 E6 proteins induce a significant decrease in the amount of human p53 protein present in these cells. This decrease is rescued following treatment for 2 h with the proteasome inhibitors, CBZ/ LLnL. The levels of p53 in the absence of E6 are also increased following proteasome inhibition, further confirming the functional nature of the proteasome machinery in the E6AP null cells. We interpret these results to indicate that the high-risk HPV E6 proteins can also target p53 for proteasome-mediated degradation in a manner that is in part independent of E6AP. The above studies demonstrate that HPV-16 and -18 E6 can degrade p53 and PDZ domain-containing substrates in an E6AP-null background. The degree of proteasome involvement, however, remains to be determined, since proteasomal inhibitor-mediated rescue of MAGI-1 and 3 was lacking, and rescue of Scrib was modest. However, such assays depend upon the rate of synthesis and the halflife of the target protein. A weakly transcribed protein with a long half-life would not be rescued in the 2 h of treatment with proteasome inhibition used here. However, assuming that MAGI-3 is expressed at a similar rate in HEK293 cells and in E6APÀ/À cells, this leads us to conclude that degradation in the presence of E6AP is proteasome mediated, whereas in the absence of E6AP an alternative pathway of degradation is being employed. Further studies are therefore required to identify the mechanism by which E6 can target these PDZ domain-containing proteins for degradation.
In the case of p53 the picture is surprisingly much clearer. Both HPV-16 and -18 E6 induce efficient degradation of p53 in these E6AP-null cells, and this appears to be proteasome-mediated. Obviously, previous studies have shown a central role for E6AP in the degradation of p53 Cooper et al., 2003; Hengstermann et al., 2005; Kelley et al., 2005) and there are likely to be significant differences between the in vivo assays and those performed in vitro (Gardiol and Banks, 1998; Liu et al., 1999) . One E6AP-null cell line that was used in similar assays with p53 concluded that E6AP was essential for p53 degradation (Cooper et al., 2003) . However, these cells were of fibroblast origin: a different lineage to the epithelially derived cells used here. In addition, they were embryonically derived, whereas our epithelial cells were derived from 9-day-old mice. Such differences could have significant effects upon the outcome of these assays, since the protein expression profiles will be very different between these two sets of cells. Other caveats include differences in the respective levels of protein expression, and whether E6 activity was being assessed in human or mouse cells. In addition, our immortalized cells also express EJ-ras and Adenovirus E1a, which may also alter the composition of the cellular proteolytic machinery. It is important to note that other studies have also found that both p53 and certain PDZ domain containing substrates of E6 can be degraded in both an E6AP-independent and a proteasome-independent manner (Camus et al., 2007; Storrs and Silverstein, 2007) .
Although the biological significance of these findings remains to be determined, it is interesting to note that similar findings were observed in studies on the in vivo activity of HPV E6 in E6AP-null, K14E6 transgenic mouse models. Specifically, K14E6 transgenic mice nulligenic for E6AP exhibit similar biological characteristics to those observed in K14E6 mice expressing wild-type E6AP, including the ability to inhibit the accumulation of p53 following irradiation (Shai et al., 2007) . These studies therefore suggest that the role of E6AP in the pathobiology of HPV infection is not as Figure 4 HPV E6 degradation of p53. 8B-9 cells were transfected with 1 mg of human p53 expression plasmid (Thomas et al., 1999a) together with 3 mg of HPV-16 or HPV-18 E6 expression plasmids as indicated, plus 2 mg of the pCDNA-HisLacZ expression plasmid (Invitrogen) or 2 mg GFP expression plasmid (Clonetech). After 24 h, the cells were incubated with CBZ/LLnL (50 mM final concentrations) for 2 h to block the proteasome. Cells were then harvested and p53 detected using western blotting with anti-p53 monoclonal antibody (1:500; DO-1, Santa Cruz distributed by D.B.A., Italia S.R.L., Milan, Italy) and either anti-b-galactosidase antibody (LacZ) or anti-GFP, followed by anti-mouse HRP conjugate and developed using ECL (Amersham). The gels were scanned and the percentage changes in p53 levels following CBZ protection (prot.), E6 degradation (degr.) and CBZ-induced recovery from degradation (rec.) are indicated. When the GFP expression levels are taken into account the recovery is in the order of 125%. The results are representative of three separate experiments.
central as was previously thought. The data presented here would suggest most strongly that HPV-16 and -18 E6 have evolved multiple mechanisms of interacting with the proteolytic machinery to bring about the destruction of their target proteins. Future studies will be focused on further defining these pathways.
